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Background: We sought to clarify the inﬂuence of the severity of obstructive sleep apnea (OSA)
on heart rate (HR) in patients with OSA.
Methods: We examined 136 patients who underwent overnight polysomnography together with
24-h Holter electrocardiography and who were diagnosed as having OSA [apnea—hypopnea index
(AHI) ≥5]. The patients were divided into the following 3 groups: 30 with 5≤ AHI <15 (group A);
33 with 15≤ AHI <30 (group B); 73 with AHI ≥30 (group C). Mean HRs during 24 h, wakefulness,
and sleep were calculated.
Results: Mean HRs during 24 h, wakefulness, and sleep were signiﬁcantly higher in group C
than in groups A and B. Mean HRs during 24 h, wakefulness, and sleep correlated positively
with AHI (Spearman’s  = 0.36, p < 0.001; Spearman’s  = 0.32, p < 0.001; Spearman’s  = 0.38,
p < 0.001; respectively). Multiple regression analyses revealed that ln AHI was independently
associated with mean HRs during 24 h, wakefulness, and sleep. In 21 OSA patients who started
nasal continuous positive airway pressure (nCPAP) therapy, mean HRs during 24 h, wakefulness,
and sleep were signiﬁcantly reduced at 6 months after the initiation of nCPAP.
Conclusion: The severity of OSA was independently associated with mean HRs during 24 h,
wakefulness, and sleep, and 6-month treatment with nCPAP reduced the values. The prognostic
signiﬁcance of elevated mean HRs during 24 h, wakefulness, and sleep is necessary to be clariﬁed
in patients with OSA.
© 2010 Japanese College of Car
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ntroductionbstructive sleep apnea (OSA) is a chronic condition char-
cterized by repetitive episodes of upper airway collapse,
pneas, and arousal during sleep. Recently, much attention
as been paid to links between OSA and various cardio-













































































































ascular diseases [1]. Previous studies have demonstrated
positive association between elevated heart rate (HR) at
est and adverse cardiovascular events in both the general
opulation and the population with cardiovascular disease
2—8]. Furthermore, elevated mean HR during 48 h was
eported to be an independent factor for cardiovascular
ortality in normotensive patients with end-stage renal
isease [9]. There are few studies investigating the inﬂu-
nce of the severity of OSA on HR in patients with OSA
10]. Sumi et al. [10] reported that mean HR during 24 h
orrelated positively with apnea—hypopnea index (AHI) in
2 patients with OSA and that mean HRs in the daytime
06:00—22:00 h) and night-time (22:00—06:00 h) were signif-
cantly reduced after 3 or 4 days of nasal continuous positive
irway pressure (nCPAP) treatment in those patients. How-
ver, their study included patients with use of beta-blockers,
hich can affect mean HR, and they did not perform a
ultivariate regression analysis to determine independent
actors related to mean HR. Therefore, it is unclear whether
ean HR is independently associated with the severity
f OSA in patients with OSA. In addition, the long-term
ffect of nCPAP therapy on mean HR is unclear. Accord-
ngly, we sought to clarify whether the severity of OSA
ndependently affects mean HRs during 24 h, wakefulness,
nd sleep in OSA patients without the use of beta-blockers
nd whether 6 months of treatment with nCPAP reduces




etween January 2006 and December 2008, we prospec-
ively performed overnight polysomnography together with
4-h Holter electrocardiography (ECG) in 214 patients who
ere clinically suspected of having sleep apnea at Oita Naka-
ura Hospital. A total of 136 patients (111 men and 25
omen, mean age 57.1± 15.6 years) who were diagnosed
s having OSA (AHI ≥5) and who did not meet the following
xclusion criteria were enrolled in this study. The exclu-
ion criteria were chronic atrial ﬁbrillation, second or third
trioventricular block, permanent pacemaker, symptoms or
igns of congestive heart failure, left ventricular ejection
raction <55%, neurological disease, use of digitalis, use
f anti-arrhythmic agents, use of beta-blockers, or use of
alcium antagonists affecting HR, including verapamil and
iltiazem. The 136 patients were classiﬁed into the following
groups based on their AHI [11]: 30 with 5≤ AHI <15 (group
); 33 with 15≤ AHI <30 (group B); and 73 with AHI ≥30
group C). Of the 136 patients, 67 patients started nCPAP
herapy. Of the 67 patients, 37 patients agreed to undergo
olysomnography and 24-h Holter ECG after 6 months of the
nitiation of nCPAP therapy. Of the 37 patients, 10 patients
uitted nCPAP therapy, and 21 patients (18 men and 3
omen, mean age 59.9± 12.7 years) completed the second
olysomnography and 24-h Holter ECG until December 2008.
he study protocol was approved by the ethics committee
t our institutions, and informed consent was obtained from
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vernight polysomnography
vernight polysomnography was performed at the ﬁrst
ight of hospital admission, using a computerized system
E-series, Compumedics Limited, Abbotsford, Australia).
his investigation consisted of monitoring of the electro-
ncephalogram, electro-oculogram, submental electromyo-
ram, electrocardiogram, thoraco-abdominal excursions,
ronasal airﬂow by an airﬂow pressure transducer, and
rterial oxygen saturation by pulse oximetry. An obstruc-
ive apnea was deﬁned as the absence of oronasal airﬂow
or ≥10 s associated with continued or increased inspira-
ory effort. A central apnea was deﬁned as the absence of
ronasal airﬂow for ≥10 s associated with an absent inspira-
ory effort. A hypopnea was deﬁned as a ≥50% reduction in
ronasal airﬂow for ≥10 s, associated with a ≥3% fall in oxy-
en saturation or an arousal. The AHI was calculated as the
ean number of apneas and hypopneas per hour of sleep.
s obstructive hypopneas cannot be deﬁnitely distinguished
rom central hypopneas, we did not calculate the central or
bstructive hypopnea index. An arousal was deﬁned as fol-
ows: an abrupt shift of electro-encephalogram frequency
ncluding alpha, theta, and/or frequencies greater than
6Hz (but not spindle) that lasts ≥3 s, with ≥120 s of stable
leep preceding the changes during sleep stage N1, N2, N3,
r R; arousal during stage R requires a concurrent increase
n the submental electromyogram lasting ≥1 s. Arousal index
as calculated as mean number of arousals per hour of
leep.
olter ECG
ogether with overnight polysomnography, 24-h Holter ECG
as performed using a digital recorder with 3 channels
RAC-3103, Nihon Koden, Tokyo, Japan). Polysomnography
nd Holter ECG were time-synchronized. Mean HRs dur-
ng 24 h, wakefulness, and sleep were calculated. Based on
he electro-encephalogram, sleep periods was deﬁned as a
eriod from the starting of sleep to the end of sleep.
tatistical analysis
ontinuous data are expressed as mean± S.D. or median
ﬁrst—third quartiles). Comparisons of categorical data
mong the 3 groups were analyzed by the Fisher’s exact
est or chi-square test. One-factor analysis of variance with
he Scheffe’s post hoc test was used for comparisons of
ormally distributed continuous data among the 3 groups.
hen continuous data were not normally distributed, the
ruskal—Wallis test with the Scheffe’s post hoc test was
sed. Pearson’s or Spearman’s rank correlation test was
sed to examine correlations between 2 continuous vari-
bles. Changes in data at baseline and at 6 months after
he initiation of nCPAP treatment were evaluated by the
aired t-test or Wilcoxon signed-rank test. Univariate and
ultiple regression analyses were performed to determineactors related to mean HRs during 24 h, wakefulness, and
leep. Logarithmically transformed values of AHI were used
n these analyses in order to ensure a normal distribution.
ultiple regression analyses were performed using variables
hat showed p < 0.3 on the univariate analyses. A p-value
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Table 1 Patient characteristics.
Variables Group A (n = 30) Group B (n = 33) Group C (n = 73) p-Value
Age (years) 52.5± 14.7 60.6± 14.6 57.4± 16.2 0.12
Male gender 20 (66.7) 24 (72.7) 67 (91.8) 0.004
BMI (kg/m2) 24.0± 3.2 24.8± 2.8 26.7± 4.2* 0.001
Hypertension 15 (50.0) 22 (66.7) 47 (64.4) 0.32
Dyslipidemia 14 (46.7) 20 (60.6) 55 (75.3) 0.02
Diabetes mellitus 2 (6.7) 9 (27.3) 20 (27.4) 0.06
Current smoker 4 (13.3) 8 (24.2) 14 (19.2) 0.55
Coronary artery disease 3 (10.0) 9 (27.3) 15 (20.5) 0.22
Medications
Calcium antagonists 9 (30.0) 14 (42.4) 31 (42.5) 0.47
ACEIs/ARBs 7 (23.3) 10 (30.3) 27 (37.0) 0.39
 blockers 2 (6.7) 2 (6.1) 5 (6.8) 0.99
Data are presented as the means± S.D. or n (%).
Group A = patients with 5≤ apnea—–hypopnea index (AHI) <15; group B = those with 15≤ AHI <30; group C = those with AHI ≥30.
BMI, body mass index; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II type 1 receptor blockers.
* p < 0.05 vs. group A.
Table 2 Overnight polysomnographic ﬁndings.
Variables Group A (n = 30) Group B (n = 33) Group C (n = 73) p-Value
Sleep period time (min) 546± 97 546± 74 559± 78 0.66
Total sleep time (min) 446± 111 419± 92 389± 106* 0.03
AHI 8.6 (7.1—11.1) 23.2 (19.4—26.8)* 54.0 (40.7—66.5)** <0.001
Obstructive apnea index 1.4 (0.3—2.5) 6.9 (2.5—9.2) 19.2 (9.4—37.8)** <0.001
Central apnea index 0.0 (0.0—0.3) 0.2 (0.0—1.3) 1.4 (0.2—3.5)** <0.001
Arousal index 22.7± 10.0 30.9± 10.0 54.2± 20.2** <0.001
Lowest SpO2 (%) 88.0± 3.5 83.8± 5.2* 77.8± 7.8** <0.001
Total time of SpO2 <90% (min) 0.2 (0.0—0.7) 3.3 (0.9—8.2) 17.0 (5.9—51.5)** <0.001
Data are presented as mean± S.D. or median (ﬁrst—third quartiles).

















2SpO2, arterial oxygen saturation.
* p < 0.05 vs. group A.
** p < 0.05 vs. groups A and B.
<0.05 was considered to be statistically signiﬁcant. Statis-
tical analysis was performed using a statistical software
package (SPSS, version 12.0J, SPSS Inc., Tokyo, Japan).
Results
Clinical characteristics of patients studied are shown in
Table 1. The prevalences of male gender and dyslipidemia
and body mass index (BMI) differed signiﬁcantly among the
3 groups. Overnight polysomnographic ﬁndings are shown in
Table 2. Total sleep time, AHI, obstructive apnea index, cen-
tral apnea index, lowest SpO2, and total time of SpO2 <90%
during sleep differed signiﬁcantly among the 3 groups.
Mean HRs during 24 h, wakefulness, and sleep were sig-
niﬁcantly higher in group C than in groups A (p < 0.05)
and B (p < 0.05) (Fig. 1). Mean HRs during 24 h, wakeful-
ness, and sleep correlated positively with AHI (Spearman’s
 = 0.36, p < 0.001; Spearman’s  = 0.32, p < 0.001; Spear-
man’s  = 0.38, p < 0.001; respectively) (Fig. 2). Mean
HRs during 24 h, wakefulness, and sleep correlated nega-
tively with the lowest SpO2 (r =−0.40, p < 0.001; r =−0.42,




HRs during 24 h, wakefulness, and sleep correlated positively
ith arousal index (r = 0.30, p < 0.001; r = 0.26, p < 0.001;
= 0.35, p < 0.001; respectively) (Fig. 4).
On univariate regression analyses, BMI, ln AHI, arousal
ndex, and lowest SpO2 were signiﬁcantly correlated with
ean HRs during 24 h, wakefulness, and sleep were, and
ge was signiﬁcantly correlated with mean HR during wake-
ulness (Table 3). On multiple regression analyses, male
ender and ln AHI were independent factors related to mean
Rs during 24 h, wakefulness, and sleep, and BMI was an
ndependent factor related to mean HRs during 24 h and
akefulness (Table 4). When lowest SpO2 was entered into
multiple regression analysis instead of ln AHI, lowest SpO2
as an independent factor related to mean HRs during 24 h,
akefulness, and sleep. When arousal index was entered
nto a multiple regression analysis instead of ln AHI, arousal
ndex was an independent factor related to mean HRs during
4 h, wakefulness, and sleep.In 21 patients who started nCPAP therapy, overnight
olysomnography together with 24-h Holter ECG was again
ndergone at 6 months after the initiation of the treat-
ent. The pressure of nCPAP was ﬁxed, with 8.1± 1.4 cm
2O, and the daily usage time of nCPAP was 6.5± 0.9 h.
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Figure 1 Mean heart rates (HRs) during 24 h (A), wakefulness (B), and sleep (C) among the 3 groups. *p < 0.05 vs. groups A and B.


















Higure 3 Association between the lowest arterial oxygen satur
B), and sleep (C).
reatment with nCPAP reduced mean HRs during 24 h,
akefulness, and sleep, without signiﬁcant changes in
MI (from 70.3± 10.0 beats/min to 65.0± 7.8 beats/min,
= 0.008; from 73.5± 10.3 beats/min to 68.6± 8.5 beats/
in, p = 0.01; from 65.7± 10.3 beats/min to 59.4± 7.7
eats/min, p = 0.009; respectively) (Table 5).iscussion
he association between the severity of OSA and HR has





m(SpO2) and mean heart rates (HRs) during 24 h (A), wakefulness
n the present study, mean HRs during 24 h, wakeful-
ess, and sleep correlated signiﬁcantly with AHI, lowest
pO2, and arousal index in patients with OSA. A multi-
le regression analysis showed that ln AHI (lowest SpO2
r arousal index) was independently associated with mean
Rs during 24 h, wakefulness, and sleep in those patients.
hus, the present study provides clear evidence regard-
ng the association between the severity of OSA and mean
Rs during 24 h, wakefulness, and sleep in patients with
SA. Furthermore, the present study indicates that 6-
onth treatment with nCPAP signiﬁcantly reduces mean
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Figure 4 Association between arousal index and mean heart rates (HRs) during 24 h (A), wakefulness (B), and sleep (C).
Table 3 Univariate regression analyses to determine factors related to mean heart rates during 24 h, wakefulness, and sleep.
Variables 24 h Wakefulness Sleep
Beta p-Value Beta p-Value Beta p-Value
Age (years) −0.12 0.18 −0.22 0.009 0.04 0.65
Male gender (0 = no, 1 = yes) −0.11 0.22 −0.09 0.28 −0.12 0.18
BMI (kg/m2) 0.35 <0.001 0.41 <0.001 0.21 0.01
Hypertension (0 = no, 1 = yes) 0.03 0.77 −0.01 0.91 0.03 0.70
Dyslipidemia (0 = no, 1 = yes) 0.08 0.34 0.09 0.29 0.06 0.46
Diabetes mellitus (0 = no, 1 = yes) 0.04 0.69 0.001 0.99 0.09 0.28
Current smoker (0 = no, 1 = yes) 0.07 0.45 0.09 0.28 −0.001 0.99
Coronary artery disease (0 = no, 1 = yes) 0.02 0.86 0.004 0.97 0.02 0.79
Ln AHI 0.34 <0.001 0.31 <0.001 0.36 <0.001
Arousal index 0.30 <0.001 0.26 0.002 0.35 <0.001
Lowest SpO2 (%) −0.40 <0.001 −0.42 <0.001 −0.36 <0.001
Calcium antagonists (0 = no, 1 = yes) 0.04 0.63 −0.002 0.98 0.09 0.28
ACEIs/ARBs (0 = no, 1 = yes) −0.05 0.58 −0.10 0.26 0.02 0.82
 blockers (0 = no, 1 = yes) −0.09 0.30 −0.14 0.11 −0.02 0.86
BMI, body mass index; AHI, apnea—hypopnea index; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II type 1 receptor
blockers.
Table 4 Multiple regression analyses to determine factors related to mean heart rates during 24 h, wakefulness, and sleep.
Variables 24 h Wakefulness Sleep
Beta p-Value Beta p-Value Beta p-Value
Age (years) −0.10 0.27 −0.15 0.10
Male gender (0 = no, 1 = yes) −0.26 0.002 −0.27 0.001 −0.23 0.007
BMI (kg/m2) 0.26 0.004 0.30 0.001 0.16 0.07
Dyslipidemia (0 = no, 1 = yes) −0.03 0.71
Diabetes mellitus (0 = no, 1 = yes) 0.05 0.57
Current smoker (0 = no, 1 = yes) 0.06 0.46
Ln AHI 0.33 <0.001 0.30 0.001 0.36 <0.001
Calcium antagonists (0 = no, 1 = yes) 0.06 0.47
ACEIs/ARBs (0 = no, 1 = yes) −0.02 0.85
 blockers (0 = no, 1 = yes) −0.10 0.18
BMI, body mass index; AHI, apnea—hypopnea index; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II type 1 receptor
blockers.
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Table 5 Changes in polysomnographic ﬁndings and mean heart rates during 24 h, wakefulness, and sleep at baseline and at 6
months after the initiation of nasal continuous positive airway pressure treatment in 21 patients with obstructive sleep apnea.
Variables Before After p-Value
BMI (kg/m2) 27.2± 5.2 27.2± 4.4 0.92
Arterial systolic blood pressure (mmHg) 130.5± 15.4 126.5± 12.2 0.25
Arterial diastolic blood pressure (mmHg) 81.0± 10.5 78.7± 12.3 0.18
Total sleep time (min) 354.0± 90.1 392.0± 101.0 0.17
AHI 56.5± 28.6 4.5± 3.2 <0.001
Lowest SpO2 (%) 74.8± 10.2 90.6± 3.2 <0.001
Total time of SpO2 <90% (min) 21.6 (8.1—67.2) 0.0 (0.0—0.2) <0.001
Mean HR during 24 h (beats/min) 70.3± 10.0 65.0± 7.8 0.008
Mean HR during wakefulness (beats/min) 73.5± 10.3 68.6± 8.5 0.01















































































tData are presented as mean± S.D. or median (ﬁrst—third quartile
BMI, body mass index; AHI, apnea—hypopnea index; SpO2, arteria
Rs during 24 h, wakefulness, and sleep in patients with
SA.
The depolarization rate of the sinoatrial node is largely
etermined by the activity of the autonomic nervous system.
herefore, HR is directly related to sympathetic activ-
ty or autonomic imbalance. The elevated mean HR in
atients with OSA is thought to be due to activated sym-
athetic nervous system. Brief episodes of apnea/hypopnea
ncrease sympathetic nervous activation by suspending the
onic inhibition of sympathetic outﬂow by pulmonary stretch
eceptors [12,13]. Hypoxia and hypercapnia with more pro-
onged apneas augment sympathetic nervous activity by
he stimulation of peripheral and central chemoreceptors
14,15]. Arousal immediately after apneic events induces
dditional surges in the sympathetic neural outﬂow [16].
he sympathetic nervous system is activated even during
akefulness in patients with OSA [17,18]. The mechanisms
or the activation of the sympathetic nervous system dur-
ng wakefulness in OSA patients are not fully understood,
ut one possibility is that increased chemoreﬂex gain by
SA results in tonic chemoreﬂex activation even during nor-
oxia, with consequent increased sympathetic activity [19].
t was demonstrated that administration of 100% oxygen,
hich can eliminate tonic chemoreﬂex drive, signiﬁcantly
owers sympathetic activity and resting HR during wakeful-
ess in patients with OSA [20], suggesting that the activation
f the sympathetic nervous system contributes mainly to
levated HR in patients with OSA.
Sumi et al. [10] previously reported that mean HRs in the
aytime and night-time periods were signiﬁcantly reduced
fter 3 or 4 days of nCPAP therapy in patients with OSA. In
he present study, mean HRs during 24 h, wakefulness, and
leep were signiﬁcantly reduced at 6 months after the ini-
iation of nCPAP therapy in patients with OSA, indicating a
ong-term favorable effect of nCPAP therapy on mean HRs
uring 24 h, wakefulness, and sleep. This is assumed to be
ecause nCPAP therapy restores sympathetic nervous system
veractivation during wakefulness as well as during sleep in
atients with OSA [21]. Alternatively, as high daily activity
s negatively associated with resting HR [22,23], an increase
n the daily activity resulting from restoration of daytime
leepiness caused by nCPAP therapy may have reduced mean




wgen saturation; HR, heart rate.
ot evaluate the daily activity, it is unclear as to whether
his mechanism can apply to the results of the present
tudy.
Previous studies have demonstrated a positive associa-
ion between elevated HR at rest and adverse cardiovascular
vents in both the general population and the population
ith cardiovascular diseases [2—8]. Regarding mean HR,
ice et al. [9] reported that elevated mean HR during 48 h
s an independent factor for cardiovascular mortality in
ormotensive patients with end-stage renal disease. Fur-
hermore, Perski et al. [24] showed that elevated mean
R measured by 24-h Holter ECG is strongly related to
he global severity of coronary atherosclerosis in young
atients after myocardial infarction, independently of sev-
ral established risk factors. Elevated mean HRs during 24 h,
akefulness, and sleep in patients with OSA may partly
xplain why patients with OSA, especially severe OSA, are at
n increased risk for future cardiovascular events [25—32].
n other words, elevated mean HRs during 24 h, wakefulness,
nd sleep may be intermediate in the putative causal path-
ay to increased cardiovascular events in patients with OSA.
he prognostic signiﬁcance of elevated HR (mean HR and
esting HR) in patients with OSA is necessary to be clariﬁed.
In the present study, gender was independently associ-
ted with mean HRs during 24 h, wakefulness, and sleep.
t has been shown that resting HR is higher in women
han in men [33,34], although the exact mechanisms for
his have not been established. In the present study, BMI
as an independent factor related to mean HRs during
4 h and wakefulness. It has been shown that BMI is posi-
ively associated with resting HR [35,36]. Because it is now
stablished that sympathetic nervous system is activated in
bese individuals [36], it is highly assumed that the acti-
ation contributes to an independent association between
MI and mean HR in patients with OSA. The mechanisms for
ympathetic nervous system activation in obese individuals
re not fully understood, but multiple factors such as lep-
in, reduced gain of the arterial baroreﬂex, chronic mental
tress, and lack of exercise (except OSA) could be responsi-
le for the activation [36].
During one event of obstructive apnea/hypopnea with
ubsequent arousal and hyperventilation, a decrease in HR
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without abnormal autonomic control [37]. This suggests that
the severity of OSA alters maximal and minimal HRs dur-
ing sleep as well as mean HR during sleep in patients with
OSA. In our patients, maximal HR during sleep correlated
positively with AHI (Spearman’s  = 0.18, p = 0.04), and min-
imal HR during sleep tended to correlate positively with AHI
(Spearman’s  = 0.15, p = 0.09). Therefore, the severity of
OSA seems to more strongly affect mean HR during sleep
rather than maximal and minimal HRs during sleep.
The present study has several certain limitations. First,
we did not evaluate the association between the severity
of OSA and resting HR. It is unclear as to whether there
are any differences in clinical and prognostic implications
between resting HR and mean HRs during 24 h, wakefulness,
and sleep. Second, we did not evaluate the physical activity
during 24-h Holter ECG recording, which would affect mean
HR during wakefulness. However, it is difﬁcult to evaluate
physical activity. Third, in the present study, the number
of patients who underwent 24-h Holter ECG at 6 months
after the initiation of nCPAP therapy was only 21, and con-
trols (no treatment with nCPAP) were not included. Finally,
we did not assess the association between mean HR and
the magnitude of the sympathetic nervous activation. We
found no signiﬁcant association between AHI and the ratio
of low-frequency power to high-frequency power, a sim-
ple marker for sympathetic nervous activity (Spearman’s
 = 0.02, p = 0.85). However, because the ratio is not a gold
standard index to evaluate sympathetic nervous activity, no
association between AHI and the ratio cannot deny the sce-
nario that activated sympathetic nervous system caused by
OSA contributes to the elevated mean HR in patients with
OSA. With regard to HR variability, Wakai et al. [38] showed
in a small sample study that patients with OSA had a greater
very low frequency power during 24 h than those without it.
However, we could ﬁnd no signiﬁcant correlation between
very low frequency power during 24 h and AHI (Spearman’s
 =−0.01, p = 0.95). The association between the severity
of OSA and very low frequency power during 24 h requires
further investigations.
In conclusion, the severity of OSA was independently
associated with elevated mean HRs during 24 h, wake-
fulness, and sleep in patients with OSA, and 6-month
treatment with nCPAP reduced the values in those patients.
The prognostic signiﬁcance of elevated mean HRs during
24 h, wakefulness, and sleep is necessary to be clariﬁed in
patients with OSA.
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